The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...
Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.
HotCopper.com on MSN3d
Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancerFor those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...
“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...
PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.
In the 17th century, diagnosing diabetes meant tasting urine for sweetness – a crude yet pioneering method that laid the foundation for modern endocrinology. Today, medical science has evolved to ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Wolfgang P.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback